Leaf Ventures Ii L.P. New Buys 270,000 Shares of Principia Biopharma Inc (PRNB) Stock

Principia Biopharma Inc (NASDAQ:PRNB) major shareholder Leaf Ventures Ii L.P. New bought 270,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 18th. The stock was purchased at an average cost of $17.00 per share, with a total value of $4,590,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

PRNB traded up $0.07 during midday trading on Friday, reaching $25.09. 160,419 shares of the company were exchanged, compared to its average volume of 99,900. Principia Biopharma Inc has a one year low of $23.95 and a one year high of $36.00.

A number of brokerages recently commented on PRNB. Robert W. Baird began coverage on Principia Biopharma in a research report on Tuesday. They issued an “outperform” rating for the company. Leerink Swann began coverage on Principia Biopharma in a research report on Tuesday. They issued an “outperform” rating and a $34.00 target price for the company. Wells Fargo & Co began coverage on Principia Biopharma in a research report on Tuesday. They issued an “outperform” rating for the company. Finally, Bank of America began coverage on Principia Biopharma in a research report on Tuesday. They issued a “buy” rating for the company.

About Principia Biopharma

Principia Biopharma Inc, a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome.

See Also: NASDAQ Stock Market Explained

Receive News & Ratings for Principia Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Principia Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply